ArticleAnnals of African medicine2025
Evaluating the Impact of Teriflunomide and Dimethyl Fumarate on Quality of Life in Relapsing-remitting Multiple Sclerosis: Insights from Eastern Saudi Arabia.
Article in Annals of African medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRelapsing-remitting multiple sclerosis (RRMS) is a chronic neurological condition prevalent in Saudi Arabia. It causes a spectrum of neurological impairments that result in functional limitations and disability. The physical and psychological burdens of multiple sclerosis (MS) significantly impact patients' health-related quality of life (HRQoL). However, research evaluating its effects on HRQoL within the Saudi context remains scarce. This study aimed to compare HRQoL among RRMS patients undergoing treatment with teriflunomide or dimethyl fumarate and identify factors influencing treatment outcomes. METHODOLOGY: A cross-sectional study involving all MS patients was conducted at King Fahd Hospital of the University from November 2022 to April 2023. Participants were categorized into two groups based on their treatment: those receiving teriflunomide and those on dimethyl fumarate. Data were collected using the EQ-5D-5L questionnaire.
resultsOf the 280 patients invited, 82 RRMS patients met the inclusion criteria, comprising 28 males and 54 females, with most participants over 40. Approximately 43.9% were treated with teriflunomide, whereas 56.1% received dimethyl fumarate. No statistically significant differences were found in the three health indicators assessed between the two treatment groups. Nonetheless, the descriptive analysis indicated that RRMS patients on dimethyl fumarate reported superior health outcomes to those on teriflunomide.
conclusionThe study revealed that patients with RRMS in the dimethyl fumarate and teriflunomide treatment groups reported low physical and mental HRQoL. While no statistically significant differences were observed between the two groups, those receiving dimethyl fumarate indicated a better QoL than their counterparts on teriflunomide. Future research is necessary to identify specific gaps that could facilitate improvements in HRQoL among RRMS patients. Furthermore, the findings from this study may inform the development and implementation of targeted intervention programs aimed at enhancing HRQoL for RRMS patients within the Saudi population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.